Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Carcinoid TumorAcromegaly
Interventions
DRUG

Pasireotide

Trial Locations (17)

1200

Novartis Investigative Site, Brussels

3000

Novartis Investigative Site, Leuven

4000

Novartis Investigative Site, Liège

10098

Novartis Investigative Site, Berlin

12203

Novartis Investigative Site, Berlin

33612

H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1), Tampa

45122

Novartis Investigative Site, Essen

80336

Novartis Investigative Site, München

90048

Cedars Sinai Medical Center SC - 4, Los Angeles

94304

Stanford University Medical Center Stanford Cancer Center (3), Stanford

77030-4009

University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology, Houston

N6A 4L6

Novartis Investigative Site, London

M5G1X5

Novartis Investigative Site, Toronto

H2L 4M1

Novartis Investigative Site, Montreal

04317

Novartis Investigative Site, Leipzig

3015 CE

Novartis Investigative Site, Rotterdam

NO-0379

Novartis Investigative Site, Oslo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY